Cancertrack™ is a comprehensive, blood-based monitoring solution designed to track cancer activity in real time. By detecting circulating tumor cells (CTCs) and tumor-derived DNA and RNA in the bloodstream, it enables continuous assessment of disease status without the need for invasive procedures. This non-invasive approach provides actionable insights into tumor dynamics, helping clinicians detect recurrence earlier, monitor treatment response, and adapt therapy with greater precision.
Enabling Proactive, Real-Time Clinical Decisions
Track cancer activity through a simple blood test without the need for repeated biopsies
Detect molecular changes early, enabling faster response to treatment effectiveness
Monitor cancer activity across all disease sites through circulating tumor DNA
Perform testing as frequently as needed for longitudinal disease tracking
Dynamic, Multi-Analyte Detection for Evolving Tumors
Simultaneous detection of CTCs, ctDNA, and RNA-based signals for comprehensive tumor assessment
Captures tumor evolution, resistance mechanisms, and emerging variants in real time
Limit of detection up to 0.1% mutant allele frequency
No dependency on tumor tissue, enabling testing even when tissue is unavailable
Actionable Insights Across the Treatment Journey
Establish circulating tumor biomarkers before initiating therapy
Evaluate response to therapy through real-time molecular changes
Identify early signals of treatment resistance and disease progression
Detect molecular relapse earlier than conventional imaging
Support timely treatment modifications based on tumor dynamics
Conventional imaging may take months to reflect treatment response or disease progression, potentially delaying critical clinical decisions. Cancertrack™ enables continuous molecular monitoring, providing early insight into tumor behavior, treatment effectiveness, and emerging resistance. This allows clinicians to intervene earlier, optimize therapy strategies, and improve overall disease management.
Quick peripheral blood collection — no tissue, no invasive procedures
Detection of live tumor signals including CTCs and circulating nucleic acids
Continuous assessment of tumor-derived signals to capture evolving molecular changes
Longitudinal comparison across timepoints to identify progression, response, or stability
Clear indicators of response, resistance, or recurrence to support timely decisions